Our Culture

Charting the uncharted territories of vascular disease doesn’t happen overnight. It takes passion, grit, and heart to never stop seeking solutions. The kind of determination that has fueled Infraredx for nearly 30 years.

READ MORE

Our Leadership

Nozomu “Fuji” Fujita

President and CEO, Infraredx, a Nipro Company General Manager, Nipro Vascular Business Division


Having been employed at Nipro for nearly 25 years, Nozomu Fujita takes the Nipro creed of “Willingness” to heart. He joined the company immediately after earning his master’s degree in engineering from the Department of Applied Chemistry at the esteemed Osaka Institute of Technology, and his career grew as Nipro continued to expand.

Steve Sum, PhD

SVP R&D, Clinical, Quality & Regulatory


Steve Sum is an academic at heart. After earning a BSc in Chemistry & Mathematics at the University of Waterloo in Ontario, Canada, he went straight on to earn a MSc in Information & Systems Science from Carleton University, and then a PhD in Chemometrics and Analytical Chemistry from the University of Delaware.

Upcoming Events

See more. Know more. Heal more.

Learn how our breakthrough technology can optimize the treatment of polyvascular disease patients.

March 9-12, 2024
CRT 2024
Washington DC
April 6-8, 2024
ACC 2024
Atlanta, GA
Booth #2417
May 28-31, 2024
NCVH 2024
New Orleans, LA
June 2-3, 2024
OPCI 2024
New York City, NY
August 7-9, 2024
SOLACI 2024
Buenos Aires, Argentina
October 27-30, 2024
TCT 2024
Washington DC
December 1-5, 2024
RSNA 2024
Chicago, IL
Booth #1735

Previous Events

January 22-25, 2024
ISET 2024
Miami, FL
November 26-29, 2023
RSNA 2023
Chicago, Illinois, USA
Booth 1253
October 23-27, 2023
TCT 2023
The Moscone Convention Center, San Francisco, CA
Booth 1937
September 21-22, 2023
AICT/AsiaPCR
SUNTEC Convention and Exhibition Center, Singapore
Nipro Booth A09
August 2-4, 2023
SOLACI-SBHCI 2023
Rio de Janeiro
Nipro LATAM - Booths 37 & 79

News

Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.

The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.

Bedford, Mass., December 22, 2021 — Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE (Non-Slip Element) ALPHA coronary dilatation balloon catheter during percutaneous coronary intervention (PCI) in patients with stenotic coronary arteries.

Read More
Infraredx, a Nipro Company, and Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and International Radiology products manufacturer, announced a collaboration between the two entities to deliver cutting-edge technologies to the U.S. market.

Infraredx, a Nipro Company, and Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and International Radiology products manufacturer, announced a collaboration between the two entities to deliver cutting-edge technologies to the U.S. market. NMC announced today that it will establish a Vascular Division in the U.S., to help build a world-class vascular product portfolio to address the unmet needs in the vascular space. This strategic move aligns with Nipro Corporation’s long-term goals to enhance patient care and expand their vascular footprint.

Read More
Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter

Following Receipt of FDA Breakthrough Device Designation, Market Leading Global Organizations Strengthen their Cooperation to Navigate U.S. Regulatory Pathway.  B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019. This announcement furthers the long-term global cooperation between the B. Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management.

Read More
Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. The randomized substudy PROSPECT ABSORB, which was simultaneously published in the Journal of the American College of Cardiology (JACC), showed treatment of high-risk vulnerable plaques with a bioresorbable vascular scaffold (BVS) was safe and substantially associated with favorable long-term clinical outcomes compared to guideline-directed medical therapy (GDMT) alone.

Read More

Careers

Thank you for your interest in employment opportunities at Infraredx, a Nipro Company.

We are happy to receive your application. If you are interested in future opportunities, please send your CV to HR@infraredx.com

© 2024 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative